Similar articles

• Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial.

  Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ; HEBE investigators. Hirsch A, et al. Am Heart J. 2006 Sep;152(3):434-41. doi: 10.1016/j.ahj.2006.02.007. Am Heart J. 2006. PMID: 16923409
• Report on the Fourth Consensus Conference on the Methodology of Clinical Trials with Anxiolytic Drugs.

  Angst J, Ansseau M, Bech P, Engel RR, Hippius H, Lader M, Lecrubier Y, Lingjaerde O, de Sousa MP, Rossi A, et al. Angst J, et al. Pharmacopsychiatry. 1993 Jan;26(1):1-5. doi: 10.1055/s-2007-1014332. Pharmacopsychiatry. 1993. PMID: 8104347 Review. No abstract available.
• Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation.

  Labar B, Bogdanić V, Nemet D, Vrtar M, Mrsić M. Labar B, et al. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:108. Bone Marrow Transplant. 1989. PMID: 2697391 Clinical Trial. No abstract available.
• Response as an end point in treatment trials for acute GVHD.

  Pavletic SZ. Pavletic SZ. Bone Marrow Transplant. 2012 Feb;47(2):161-3. doi: 10.1038/bmt.2011.59. Bone Marrow Transplant. 2012. PMID: 22314205 No abstract available.
• Allogeneic bone marrow transplantation for leukemia.

  Butturini A, Gale RP. Butturini A, et al. Curr Opin Hematol. 1994 Nov;1(6):402-5. Curr Opin Hematol. 1994. PMID: 9371313 Review.